Search
Ecopipam
go.drugbank.com/drugs/DB12273InvestigationalEcopipam has been used in trials studying the treatment of Tourette's Syndrome, Lesch-Nyhan Disease, Pathological Gambling, and Self-injurious Behavior.
Zelquistinel
go.drugbank.com/drugs/DB19336InvestigationalZelquistinel is under investigation in clinical trial NCT06547489 (GATE-251 or Placebo for the Reduction of Symptoms of Major Depressive Disorder).
Emibetuzumab
go.drugbank.com/drugs/DB11849InvestigationalEmibetuzumab has been used in trials studying the treatment of Advanced Cancer, Renal Cell Carcinoma, Hepatocellular Cancer, Gastric Adenocarcinoma, and Non-Small Cell Lung Cancer, among others.
Bavisant
go.drugbank.com/drugs/DB12299InvestigationalBavisant has been used in trials studying the basic science and treatment of Alcoholism, Pharmacokinetics, Drug Interactions, Attention Deficit Hyperactivity Disorder, and Attention Deficit Disorders With
Fresolimumab
go.drugbank.com/drugs/DB12396InvestigationalFresolimumab has been used in trials studying the treatment of Primary Brain Tumors, Metastatic Breast Cancer, Diffuse Systemic Sclerosis, Pleural Malignant Mesothelioma, and Primary Focal Segmental Glomerulosclerosis
Lumretuzumab
go.drugbank.com/drugs/DB12683InvestigationalLumretuzumab has been used in trials studying the treatment of Neoplasms, Breast Cancer, Squamous Non-Small Cell Lung Cancer, and Non-Squamous Non-Small Cell Lung Cancer.
ENTR-601-44
go.drugbank.com/drugs/DB17836InvestigationalENTR-601-44 is an exon 44 skipping phosphorodiamidate morpholino oligonucleotide (PMO). Developed by Entrada Therapeutics, it was investigated for the treatment of Duchenne muscular dystrophy.[L46641]
Skin-derived ABCB5-positive Mesenchymal Stem cells
go.drugbank.com/drugs/DB17862InvestigationalSkin-derived ABCB5-positive Mesenchymal Stem cells are under investigation in clinical trial NCT04971161 (Allogeneic Abcb5-positive Dermal Mesenchymal Stromal Cells for Treatment of CVU (Phase Iib)).
Synonyms: allo-APZ2-EBGB-13
go.drugbank.com/drugs/DB18387ExperimentalGB-13 is a genetically engineered recombinant protein consisting of an IL13Ra2-targeted genetically engineered mutant of IL-13 and PE4E, a derivative of Pseudomonas exotoxin A.
PAS-004
go.drugbank.com/drugs/DB18611InvestigationalPAS-004 is an allosteric MEK 1/2 inhibitor being developed by Pasithea Therapeutics. It is being investigated for the treatment of neurofibromatosis 1 and Noonan syndrome.